InventisBio (SH:688382) Zheng Quan Zhi Xing·2025-07-30 00:11Group 1 - Qianyi Investment recently conducted research on Yifang Biotechnology, highlighting the latest progress of several investigational drugs [1] - D-2570 is planned for clinical exploration in multiple autoimmune diseases, with Phase II clinical trials for ulcerative colitis already initiated [1] - Gexuolei Tablets (brand name Anfangning) received approval from the National Medical Products Administration for market launch in November 2024, targeting adult patients with advanced non-small cell lung cancer harboring KRS G12C mutations who have undergone at least one systemic treatment [1] - D-0502 is undergoing Phase III clinical trials both domestically and internationally, showing promising safety and anti-tumor effects [1] - D-0120 has completed Phase IIb clinical trials, while preclinical studies for YF087 and YF550 have made progress [1]